CD163 and metabolic dysfunction-associated steatotic liver disease: sCD163 might also reflect treatment response, as decreasing circulating expression levels were observed in obese patients undergoing bariatric surgery (130), and NAFLD patients undergoing life-style intervention (135, 136)